Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer
Leap Therapeutics and BeiGene have started dosing patients in a trial combining an anti-PD-1 antibody with the novel targeted drug DKN-01 in... Read More
RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
RemeGen announced a 24% response rate in a clinical trial of its antibody drug conjugate RC48 in patients with HER-2 positive gastric... Read More
Immunotherapy with Anti-PD-1 Effective for Patients with Solid Tumors
A review of 13 clinical trials published in JAMA Oncology found that patients with solid tumors, including stomach tumors, had better survival... Read More
BeiGene bags option on Leap cancer drug, requests PD-1 combination trial
BeiGene and Leap Therapeutics have teamed up to study a combination of an anti-DKK1 antibody with the anti-PD-1 antibody tislelizumab in patients... Read More
BeiGene bags option on Leap cancer drug, requests PD-1 combination trial
BeiGene and Leap Therapeutics have teamed up to study a combination of an anti-DKK1 antibody with the anti-PD-1 antibody tislelizumab in patients... Read More
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
A new study published in The Lancet finds Keytruda, the PD-1 antibody pembrolizumab, may offer a better safety profile but does not... Read More
Daiichi Sankyo Presents Long-Term Phase 1 Results of Antibody Drug Conjugate DS-8201 in Patients with HER2-Expressing Breast, Gastric and Other Solid Cancers at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
New research presented at the American Society of Clinical Oncology annual conference this month shares the comprehensive research program is underway to... Read More
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
A phase III trial in The Lancet found the addition of rilotumumab (an antibody that targets the hepatocyte growth factor) to chemotherapy... Read More
